February 12, 2019
The health ministry’s Council on Unapproved Drugs and Indications with Unmet Medical Needs determined on February 6 that a high unmet medical need exists for additional indications for Otsuka Pharmaceutical’s busulfan and Novartis Pharma’s octreotide. The council will issue development...read more